Russ Conroy

Pooled analysis data support atezolizumab continuation as a viable second-line therapy option in extensive-stage small cell lung cancer.

Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

Updated findings from the MAIA trial support the use of frontline daratumumab plus lenalidomide/dexamethasone in transplant-ineligible NDMM.

Combining pembrolizumab with pemetrexed met the primary end point of objective response rate in a phase 2 trial.

Data from the RATIONALE-306 trial support the approval of tislelizumab plus chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma.

Data from the DESTINY-Breast06 trial support the positive opinion on trastuzumab deruxtecan as a treatment in HER2-low or HER2-ultralow breast cancer.

The absence of a PFS and OS benefit in the transplant arm was consistent across key subgroups in the phase 3 GMMG ReLApsE trial.

Pathologic complete response rates with the atezolizumab combination were higher for patients with PD-L1–negative disease in the phase 2 ATHENE trial.

Data highlight a need for randomized clinical trials to compare the efficacy and safety of VRD vs VTD in transplant-eligible multiple myeloma.

Data from the phase 3 STARGLO study support the CHMP’s recommendation for approving glofitamab plus gemcitabine/oxaliplatin in relapsed/refractory DLBCL.

Phase 2 data support the use of a modified quadruplet regimen omitting dexamethasone after 2 cycles in elderly transplant-ineligible multiple myeloma.

Prior data support the ability of PATHOMIQ_PRAD to predict patients at a high risk of biochemical recurrence and metastasis.

Factors such as World Health Organization status appeared to correlate with early mortality in an elderly non–small cell lung cancer cohort.

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.

Treatment with mobocertinib produces clinically meaningful delays in time to deterioration among patients enrolled on the phase 3 EXCLAIM-2 trial.

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Investigators of a phase 2 study will continue to assess long-term efficacy and quality-of-life outcomes in those who receive lenvatinib/pembrolizumab.

Data from RELATIVITY-047 show consistent benefits with nivolumab/relatlimab across most patient subgroups, including those with BRAF-mutated disease.

The safety profile of dato-DXd in the phase 1 TROPION-PanTumor01 trial is comparable with prior reports of the agent.

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Data from the CheckMate 7FL trial may inform treatment decisions regarding preoperative immunotherapy for patients with breast cancer.

The 2025 Genitourinary Cancers Symposium will feature key updates in the management of different bladder, prostate, and kidney cancer populations.

Data from the ECHELON-3 trial support the approval of the brentuximab vedotin combo in relapsed/refractory B-cell lymphoma.

Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.

Adding panitumumab to sotorasib has yielded higher responses rates in KRAS G12C-mutated CRC compared with prior standards of care.

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.

Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.